To address the challenges in selecting optimal ctDNA-MRD detection technologies, Genecast has pioneered MRD MinerVa Prime—a novel integrated solution. 

To learn more about Genecast MRD MinerVa Prime, please visit.

About MinerVa Prime

The MinerVa Prime technology platform utilizes WES Prime—a whole-exome sequencing solution specifically developed for pan-solid tumors—to perform comprehensive tumor tissue mutation profiling. By strategically deepening coverage of critical genomic regions, it achieves enhanced precision in therapy-relevant variant detection.

MinerVa Prime delivers ultra-sensitive MRD monitoring through:

• Personalized 50-variant panels tailored per patient's tumor profile

• 100,000×ultra-deep sequencing of plasma ctDNA

• Industry-leading sensitivity:

• LoD 0.0025% (16× more sensitive than consensus 0.02% threshold*)

• >99.5% specificity

Clinically Validated Performance of MinerVa Prime:

The EVIDENCE trial—China's first randomized Phase III study (NCT05325346) evaluating adjuvant therapy in EGFR-positive NSCLC—has validated MinerVa Prime's clinical utility. Key findings presented orally at 2024 WCLC:

1、Negative Predictive Value (NPV):

• 91.3% for recurrence prediction via dynamic MRD monitoring

2、Early Warning Advantage:

• Detects molecular relapseby a median of 168 days than radiographic imaging